LONDON and PHILADELPHIA, Sept. 14, 2026 (GLOBE NEWSWIRE) — Avacta Therapeutics (AIM: AVCT), a clinical stage biopharmaceutical company developing pre|CISION®, a tumor-activated oncology delivery platform, today announced the appointment of the seasoned biotech executive Mr. Mats Blom as a member of its Board of Directors and Chair of the Audit Committee.  

As part of this Board evolution, Mr. Paul Fry has indicated his intention to step down from the Board effective 30 September 2026, allowing for an orderly transfer of his responsibilities to Mr. Blom.

Christina Coughlin, CEO of Avacta, commented:

“I am delighted to welcome Mats Blom to the Avacta Board. His deep financial expertise and extensive experience in the biotechnology and life sciences sectors across the US and Europe will be instrumental as we advance our pre|CISION® platform and deliver on our clinical and strategic milestones.

“His leadership and experience further enhance our governance, supporting our mission to bring innovative cancer therapies to patients and create long-term value for shareholders.

“On behalf of the Board, I would also like to thank Paul Fry for his commitment to the Company over the last 7 years and wish him well for the future.”

Mats Blom, member of the Board of Directors and Chair of the Audit Committee, added:

“I am honored to join Avacta’s Board and take on the role of Audit Committee Chair at such a transformative time for the company. The pre|CISION® platform holds significant promise for patients with cancer, and I look forward to contributing my financial and governance experience to support the executive team in executing on its strategic vision and ensuring the highest standards of oversight as we continue to progress the pipeline and engage with potential partners.”

Mr. Blom is an experienced biotechnology finance executive and Board member with a strong track record as Chief Financial Officer in several life sciences companies, including at Zealand Pharma A/S from 2010-2019, where he oversaw both its listing on Nasdaq and previous initial public offering on Nasdaq OMX Copenhagen. He was also CFO of Active Biotech and Anoto Group, both listed on European exchanges, and private companies NorthSea Therapeutics USA Inc, Modus Therapeutics and Swedish Orphan International.

He is currently Chairman of the Board of Egetis Therapeutics AB and Board member at Hansa Biopharma AB, both listed on the Nasdaq Stockholm exchange, and Board member at privately held Pephexia Therapeutics ApS, and was previously a Board member at Nasdaq-listed Altamira Therapeutics. Earlier in his career, Mr. Blom was a management consultant at Gemini Consulting and Ernst & Young. He holds a BA in Business Administration and Economics from Lund University and an MBA from the IESE University of Navarra, Barcelona.

-Ends-

For further information from Avacta, please contact:

Avacta Group plc
Christina Coughlin, Chief Executive Officer
https://avacta.com/
via Cohesion Bureau
Strand Hanson Limited (Nominated Adviser)
James Harris / Chris Raggett / James Dance
www.strandhanson.co.uk
   
Zeus (Broker)
James Hornigold / George Duxberry / Dominic King
www.zeuscapital.co.uk
   
Cohesion Bureau
Communications / Media / Investors
Richard Jarvis
avacta@cohesionbureau.com

 

   

About Avacta – https://avacta.com/

Avacta Therapeutics is a clinical-stage life sciences company expanding the reach of highly potent cancer therapies through its proprietary pre|CISION® platform. pre|CISION® is a payload delivery system based on a tumor-specific protease (Fibroblast Activation Protein or FAP) that is designed to concentrate highly potent payloads in the tumor microenvironment while sparing normal tissues. Avacta’s innovative pre|CISION® peptide drug conjugates (PDC) are a novel entry to the XDC drug class, leveraging the success of antibody drug conjugates with alternative methods of delivery beyond antibodies. 

Our pre|CISION® PDCs leverage this tumor-specific release mechanism to provide unique benefits over traditional antibody drug conjugates, releasing active payload in the tumor and reducing systemic exposure and toxicity which enables dosing to be optimized to deliver the best outcomes for patients. The lead clinical program is faridoxorubicin (AVA6000), a Gen One FAP-enabled pre|CISION® version of doxorubicin that delivers the payload directly in the tumor with limited peripheral blood exposure and has demonstrated preliminary activity in tumor types sensitive to doxorubicin including salivary gland cancer and soft tissue sarcoma. 

Further Information Pursuant to Rule 17 and Schedule 2(g) of the AIM Rules for Companies

Mr Blom, aged 61, currently holds or has held the following directorships or partnerships in the past five years:

Current Directorships/Partnerships Past Directorships/Partnerships within the last five years
Egetis Therapeutics AB Altamira Therapeutics Ltd
Egetis Therapeutics Incentive AB Altamira Medica Limited
Rare Thyroid Therapeutics International AB NorthSea Therapeutics USA Inc
Hansa Biopharma AB  
Pephexia Therapeutics ApS  
MPB Advisory AB  
   

Mr Blom currently holds no ordinary shares in the Company. There are no further disclosures required in accordance with AIM Rule 17 or Schedule 2(g) of the AIM Rules for Companies in respect of the appointment of Mr Blom.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

Aspo Plc Investor news 14 September 2026 at 9.00 EEST

ESL Shipping signs major transport agreement with Stegra

ESL Shipping has signed a significant agreement with Stegra for the transport of raw materials and finished steel products. Stegra is currently building its first large-scale plant for the production of near-zero-emission steel in Boden, Sweden.

The agreement establishes a foundation for cooperation between the two companies and strengthens ESL Shipping’s position as a trusted maritime transport partner for industrial customers in Northern Europe.

“Securing a long-term agreement with Stegra is an important achievement for ESL Shipping. We are pleased to support Stegra with reliable maritime logistics and look forward to building a successful long-term partnership. The agreement is a strong endorsement of our ability to serve demanding industrial supply chains in Northern Europe,” says Mikki Koskinen, Managing Director of ESL Shipping.

“Maritime transport is a critical part of our logistics network, and having the right partners is essential to our success. ESL Shipping’s experience in Northern Europe and our shared ambition for decarbonization and sustainability make the company an important partner in the seagoing supply chains supporting our operations in Boden,” says Jenny Marin, Head of Logistics, Stegra.

ESL Shipping is currently implementing a fleet renewal investment programme comprising twelve 5,400 dwt Green Coaster vessels and four 17,000 dwt Green Handy vessels. Green Handy vessels are equipped with methanol dual-fuel propulsion.

For more information, please contact:
Mikki Koskinen, Managing Director, ESL Shipping, tel. +358 50 351 7791, firstname.lastname@eslshipping.com

eslshipping.com/

About Stegra
Stegra is an industrial impact scale-up in the process of building its first plant for large-scale production of green hydrogen, green iron and green steel. The company was founded in 2020 as H2 Green Steel and changed name to Stegra in 2024 to reflect its purpose to decarbonize hard-to-abate industry, starting with steel. Stegra’s flagship plant is being built in Boden, northern Sweden, and its headquarters are in Stockholm. stegra.com

Aspo creates value by owning and developing business operations sustainably and in the long term. Aspo’s businesses – ESL Shipping and Telko – enable future-proof, sustainable choices for customers in various industries. Established in 1929, today we are together about 650 experts on land and at sea. While the Nordic region is our core market, we serve our customers with world-class solutions in 18 countries around Europe and parts of Asia.

Aspo is listed on Nasdaq Helsinki and is headquartered in Finland.

Aspo – Sustainable value creation

ST SafeSense VD56GA automotive image sensor

ST SafeSense VD56GA automotive image sensor
ST SafeSense VD56GA automotive image sensor

STMicroelectronics introduces automotive image sensor
to help scale affordable in-cabin sensing

  • Helps OEMs and Tier 1s bring driver and occupant monitoring to high-volume vehicle platforms with lower system cost
  • Delivers 35% higher image sharpness and nearly 60% higher infrared sensitivity than the previous generation in a compact 1.1 MP automotive image sensor

Geneva, Switzerland, September 14, 2026 – STMicroelectronics (NYSE: STM), a global semiconductor leader serving customers across the spectrum of electronics applications, introduces ST SafeSense VD56GA, a new 1.1 MP automotive image sensor for infrared in-cabin sensing that helps OEMs and Tier 1 suppliers scale driver and occupant monitoring across vehicle lines while balancing performance, integration, and cost.

As driver and occupant monitoring moves into more vehicle platforms, automotive manufacturers and suppliers are looking for imaging solutions that support strong in-cabin performance without adding unnecessary system cost or design complexity. VD56GA meets that need with a compact sensor architecture, high infrared sensitivity, and embedded image-processing features that can help simplify camera design and integration. The sensor is designed to give camera developers the image quality needed for driver and occupant monitoring while preserving the size and cost advantages of a compact format. In many in-cabin use cases, this can help customers meet performance targets without moving to a larger, more expensive sensor.

“In-cabin sensing is moving beyond premium platforms, and carmakers need cost-effective solutions they can deploy broadly,” said Alexandre Balmefrezol, Executive Vice President and General Manager of the Imaging Sub-Group at STMicroelectronics. “With VD56GA, we focused on the system-level tradeoffs that matter most: image quality in infrared conditions, compact integration, and a cost structure that supports high-volume programs. Equally important, the sensor benefits from ST’s Integrated Device Manufacturer model, with front-end manufacturing in Crolles, France, giving customers greater supply-chain resilience, quality control, and long-term support for automotive programs.”

“As driver and occupant monitoring systems move into a broader range of vehicle platforms, OEMs are increasingly focused on solutions that can be deployed at scale, with volumes set to exceed 70 million units by 2031. Success in this market depends not only on imaging performance, but also on reducing system cost, simplifying integration, and enabling adoption across high-volume vehicle programs,” (*) underlined Anas Chalak, Market & Technology Analyst, Imaging at Yole Group.

Helping carmakers scale driver and occupant monitoring

VD56GA is designed to help reduce the cost of the complete camera module. Its imaging performance enables the use of lower-cost optics, simplified infrared illumination, less demanding optical filtering, and no external image-processing. For OEMs and Tier 1s, that can translate into a more cost-effective path to deploying driver and occupant monitoring across a broader range of vehicle programs.

The sensor leverages a new backside-illuminated pixel architecture, called ST DeepNIR, optimized for infrared imaging. With 35% higher modulation transfer function (MTF) sharpness and nearly 60% higher quantum efficiency than the previous generation, VD56GA is currently the only sensor in its class to achieve this level of combined optical resolution and infrared sensitivity, helping in challenging conditions like under display camera.

By extracting more performance from a compact 1.1 MP architecture, VD56GA helps automotive designers achieve the image quality required for advanced sensing functions, while benefiting from the integration and cost advantages of a compact sensor architecture.

Compact integration with embedded image processing

Designed for modern automotive camera modules, VD56GA is housed in a compact 3.7 mm x 3.2 mm CSP package, making it suitable for space-constrained installations and next-generation in-cabin camera designs.

The device also integrates a range of embedded image-processing functions, including mirror, crop, dark calibration, auto exposure, and piecewise-linear processing. These features remove the need for external image-processing resources, simplify camera design and speed development.

Support for both RAW and YUV output formats give OEMs and Tier 1 suppliers flexibility across different electronic architectures and software environments, making it easier to adapt the device to a broad range of implementation strategies.

Building on ST’s automotive imaging leadership

VD56GA builds on ST’s established presence in automotive imaging and in-cabin sensing. Earlier this year, ST announced shipment of its 10 millionth automotive of SafeSense by ST image sensors, reflecting broad adoption across key automotive regions, including Europe, Asia, and the United States.

Customers benefit from ST’s vertically integrated manufacturing model and secure supply chain, with front-end manufacturing of VD56GA takes place at ST’s facility in Crolles, France and packaging in Asia; reinforcing the company’s focus on industrial resilience, product quality, and supply continuity for automotive customers worldwide.

Availability

Samples are available now. Pricing information and sample requests are available from local ST sales offices.

Learn more: https://www.st.com/en/imaging-and-photonics-solutions/vd56ga.html  

*Source: Status of CMOS Image sensors industry 2026 report, Yole Group

About STMicroelectronics

At ST, we are 49,000 creators and makers of semiconductor technologies mastering the semiconductor supply chain with state-of-the-art manufacturing facilities. An integrated device manufacturer, we work with more than 200,000 customers and thousands of partners to design and build products, solutions, and ecosystems that address their challenges and opportunities, and the need to support a more sustainable world. Our technologies enable smarter mobility, more efficient power and energy management, and the wide-scale deployment of cloud-connected autonomous things. We are on track to be carbon neutral in all direct and indirect emissions (scopes 1 and 2), product transportation, business travel, and employee commuting emissions (our scope 3 focus), and to achieve our 100% renewable electricity sourcing goal by the end of 2027. Further information can be found at www.st.com.

For further information, please contact:

INVESTOR RELATIONS
Jérôme Ramel
EVP Corporate Development & Integrated External Communication
Tel: +41 22 929 59 20
jerome.ramel@st.com

MEDIA RELATIONS
Alexis Breton
Group VP Corporate External Communications
Tel: +33 6 59 16 79 08
alexis.breton@st.com

Attachments

  • All 24 patients completed treatment with no dose-limiting toxicities, no Grade 3 or higher adverse events related to JNJ-1900 (NBTXR3 or to the injection procedure, and intratumoral injection was deemed feasible
  • One-year locoregional control rate was 79%, one-year local progression-free survival (LPFS) was 61%, and one-year overall survival (OS) was 70% in evaluable subjects— achieved at a lower re-irradiation dose than patients’ prior course of radiotherapy
  • Investigators concluded that JNJ-1900 (NBTXR3 may permit clinically meaningful local control using a substantially lower re-irradiation dose than patients’ prior course of radiotherapy
  • Enrollment in the dose-escalation and expansion parts of the study is complete per protocol; following the encourage findings, additional patient enrollment in this study is planned

Data presented at the IASLC 2026 World Conference on Lung Cancer

PARIS and CAMBRIDGE, Mass., Sept. 14, 2026 (GLOBE NEWSWIRE) — NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the “Company”), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced updated safety and efficacy data from the completed dose-escalation and expansion phases of a Phase 1 study sponsored by The University of Texas MD Anderson Cancer Center (“UT MD Anderson”) evaluating radiotherapy-activated JNJ-1900 (NBTXR3) for patients with inoperable, locoregionally recurrent non-small cell lung cancer (“NSCLC”) amenable to re-irradiation (“reRT”). The data were presented by study principal investigator Saumil Gandhi, MD, PhD, at the International Association for the Study of Lung Cancer (“IASLC”) 2026 World Conference on Lung Cancer (“WCLC”), taking place September 12–15, 2026 in Seoul, Republic of Korea.

POSTER P2.260: Re-irradiation (ReRT) with NBTXR3 for Inoperable Locoregionally Recurrent Non-Small Cell Lung Cancer (NSCLC): A Phase I Trial

Saumil N. Gandhi, MD, PhD; Enoch Chang, MD; Aileen B. Chen, MD; Stephen G. Chun, MD; Joe Y. Chang, MD, PhD; Steven H. Lin, MD, PhD; Matthew S. Ning, MD, MPH; David Qian, MD; Julianna K. Bronk, MD, PhD; Rahul A. Sheth, MD; Jianjun Zhang, MD, PhD; Tina Cascone, MD, PhD; Marcelo Vailati Negrao, MD; Anne S. Tsao, MD; George R. Blumenschein, MD; Mehmet Altan, MD; John V. Heymach, MD, PhD; James W. Welsh, MD; Suyu Liu, PhD; Zhongxing Liao, MD; Roberto F. Casal, MD — The University of Texas MD Anderson Cancer Center

Patients who are candidates for re-irradiation are frequently limited to palliative radiation doses because of normal-tissue tolerance, and their recurrent tumors typically harbor the most radiation-resistant cells. Effective strategies to safely deliver radiotherapy doses capable of controlling recurrent tumors remain a significant unmet need in this setting.

“Recurrence within a previously irradiated field is one of the least forgiving problems in thoracic oncology,” said Saumil Gandhi, MD, PhD, Department of Thoracic Radiation Oncology, Division of Radiation Oncology at UT MD Anderson. “The normal tissue near the tumor has already received a full course of radiation, so the dose that can delivered safely during a second course is limited. Additionally, the disease that returns is often more radioresistant because it survived radiation the first time. In this study, JNJ-1900 (NBTXR3) was delivered without dose-limiting toxicities, and we observed clinically meaningful local control at a substantially lower re-irradiation dose. These findings warrant evaluation in a randomized trial.”

Results from the pooled dose-escalation and expansion phases showed that all 24 patients completed treatment with JNJ-1900 (NBTXR3) plus re-irradiation with no dose-limiting toxicities. Investigators reported no Grade 3 or higher adverse events related to JNJ-1900 (NBTXR3) or to the injection procedure.

Grade 3 radiotherapy-related adverse events occurred in 33% of patients (n=8), and Grade 5 radiotherapy-related adverse events in 8% (n=2). The recommended Phase 2 dose was established at 33% of gross tumor volume.

At a median follow-up of 12 months (data cutoff: August 2026) the one-year locoregional control rate was 79%. One-year local progression-free survival (“LPFS”) was 61% (median 13.6 months), and one-year overall survival (“OS”) was 70% (median 14.8 months). Investigators concluded that JNJ-1900 (NBTXR3) may permit clinically meaningful local control using a substantially lower re-irradiation dose.

“The Nanobiotix team is encouraged by these full-cohort findings in one of the most difficult settings in lung cancer,” said Louis Kayitalire, MD, Chief Medical Officer of Nanobiotix. “If a physics-based approach can improve local control in tissue that has already failed radiation, and do so at a reduced dose, then the conditions in earlier settings, where full-dose radiotherapy reaches previously untreated tissue, could be even more favorable. We look forward to further evaluation in additional patients enrolled to this study and across indications.”

Enrollment in both the dose-escalation and expansion parts of the study is complete per protocol. Following the encouraging findings, additional patient enrollment in this study is planned.

About JNJ-1900 (NBTXR3)

JNJ-1900 (NBTXR3) is a novel, potentially first-in-class oncology product composed of functionalized hafnium oxide nanoparticles administered via one-time intratumoral injection and activated by radiotherapy. The product candidate’s mechanism of action (MoA) is designed to induce significant tumor cell death in the injected tumor when activated by radiotherapy, subsequently triggering adaptive immune response and long-term anti-cancer memory. Proof-of-concept was demonstrated in a randomized Phase 2/3 soft tissue sarcoma study sponsored by Nanobiotix in 2018.

Radiotherapy-activated JNJ-1900 (NBTXR3) is being evaluated across multiple solid tumor indications as a single agent or combination therapy. Given the Company’s focus areas, and balanced against the scalable potential of NBTXR3, Nanobiotix has engaged in a collaboration strategy to expand development of the product candidate in parallel with its priority development pathways. Pursuant to this strategy, in 2019 Nanobiotix entered into a broad, comprehensive clinical research collaboration with The University of Texas MD Anderson Cancer Center to sponsor several Phase 1 and Phase 2 studies evaluating JNJ-1900 (NBTXR3) across tumor types and therapeutic combinations.

In February 2020, the United States Food and Drug Administration granted regulatory Fast Track designation for the investigation of NBTXR3 activated by radiation therapy, with or without cetuximab, for the treatment of patients with locally advanced HNSCC who are not eligible for platinum-based chemotherapy.

In 2023, Nanobiotix announced a license agreement for the global development and commercialization of JNJ-1900 (NBTXR3) with Janssen Pharmaceutica NV, a Johnson & Johnson company. Studies being led by Johnson & Johnson include NANORAY-312 (NCT04892173), a global, randomized Phase 3 study in platinum-based chemotherapy-ineligible, locally advanced head and neck squamous cell cancers; LUMIRAY (NCT07219212), a global, phase 1b, open-label study in locally advanced head and neck squamous cell cancers; and CONVERGE (NCT06667908), a phase 2, randomized, open-label, active-controlled study in locally advanced and unresectable Stage III non-small cell lung cancer (NSCLC).

About NANOBIOTIX

Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The Company’s philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life.

Incorporated in 2003, Nanobiotix is headquartered in Paris, France and is listed on Euronext Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020. The Company has subsidiaries in Cambridge, Massachusetts (United States) amongst other locations.

Nanobiotix is the owner of more than 30 umbrella patents associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system.

For more information about Nanobiotix, visit us at www.nanobiotix.com or follow us on LinkedIn and Twitter

Disclaimer

This press release contains “forward-looking” statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the use of proceed therefrom, and the period of time through which the Company’s anticipates its financial resources will be adequate to support operations. Words such as “expects”, “intends”, “can”, “could”, “may”, “might”, “plan”, “potential”, “should” and “will” or the negative of these and similar expressions are intended to identify forward-looking statements. These forward-looking statements which are based on the Company’ management’s current expectations and assumptions and on information currently available to management. These forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from those implied by the forward-looking statements, including risks related to Nanobiotix’s business and financial performance, which include the risk that assumptions underlying the Company’s cash runway projections are not realized. Further information on the risk factors that may affect company business and financial performance is included in Nanobiotix’s Annual Report on Form 20-F filed with the SEC on April 2, 2025 under “Item 3.D. Risk Factors”, in Nanobiotix’s 2024 universal registration document filed with the AMF on April 2, 2025 under “chapter 1.5 Risk Factors”, and subsequent filings Nanobiotix makes with the SEC and AMF from time to time, including the Half-Year Report at June 30, 2025 which are available on the SEC’s website at www.sec.gov and on the AMF’s website at www.amf.org, The forward-looking statements included in this press release speak only as of the date of this press release, and except as required by law, Nanobiotix assumes no obligation to update these forward-looking statements publicly.

Nanobiotix
Communications Department
Brandon Owens
VP, Communications
+1 (617) 852-4835
contact@nanobiotix.com
Investor Relations Department
Joanne Choi
VP, Investor Relations (US)
+1 (713) 609-3150
joanne.choi@nanobiotix.com 

Ricky Bhajun
Director, Investor Relations (EU)
+33 (0) 79 97 29 99
investors@nanobiotix.com

Media Relations
France – HARDY
Caroline Hardy
+33 06 70 33 49 50
carolinehardy@outlook.fr

Global – uncapped
Becky Lauer
+1 (646) 286-0057
uncappednanobiotix@uncappedcommunications.com

Attachment

AS Tallinna Sadam’s subsidiary, OÜ TS Shipping, has signed an agreement with Aibel Seatrium Consortium ANS to charter the multifunctional icebreaker MPSV Botnica as an accommodation vessel for the project in the North Sea.

The estimated duration of the charter is 30 days, with options for extension. Charter will start in September 2026.

According to agreement with the Estonian Transport Administration, Botnica provides icebreaking services in Estonian coastal waters from December 20 to April 20.

Tallinna Sadam is one of the largest cargo- and passenger port complexes in the Baltic Sea region. In addition to passenger and freight services, Tallinna Sadam group also operates in shipping business via its subsidiaries – OÜ TS Laevad provides ferry services between the Estonian mainland and the largest islands, and OÜ TS Shipping charters its multifunctional vessel Botnica for icebreaking and offshore services in Estonia and projects abroad. Tallinna Sadam group is also a shareholder of an associate AS Green Marine, which provides waste management services.

Additional information:

Angelika Annus
Head of Investor Relations
Tel. +372 5649 6230
angelika.annus@ts.ee

The share repurchase programme runs as from 5 February 2026 and up to and including 29 January 2027 at the latest. In this period, Jyske Bank will acquire shares with a value of up to DKK 3 billion, cf. Corporate Announcement No. 11/2026 of 5 February 2026. The share repurchase programme is initiated and structured in compliance with the Market Abuse Regulation (Regulation (EU) No 596/2014) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (together with the Market Abuse Regulation, the “Safe Harbour Rules”).

The following transactions have been made under the program:

  Number of
shares
Average purchase
price (DKK)
Transaction
value (DKK)
Accumulated, previous announcement 1,916,299 941.89 1,804,942,913
7 September 2026 10,491 1.101.07 11,551,339
8 September 2026 10,529 1.093.86 11,517,302
9 September 2026 10,954 1.083.08 11,864,007
10 September 2026 10,043 1.092.87 10,975,653
11 September 2026 9,798 1.100.41 10,781,786
Accumulated under the programme 1,968,114 945.90 1,861,633,000

Following settlement of the transactions stated above, Jyske Bank will own a total of 1,968,114 of treasury shares, excluding investments made on behalf of customers and shares held for trading purposes, corresponding to 3.38% of the share capital.

Attached to this corporate announcement, aggregated details on the transactions related to the share repurchase programme are shown by venue.
                                                         
Yours faithfully,
Jyske Bank

Contact: Birger Krøgh Nielsen, CFO, tel. +45 25 26 92 42

Attachment

Sampo plc, stock exchange release, 14 September 2026 at 8:30 am EEST

Sampo plc’s share buybacks week 37/2026

During week 37 (7 September 2026 – 11 September 2026), Sampo plc (business code 0142213-3, LEI 743700UF3RL386WIDA22) has acquired its own A shares (ISIN code FI4000552500) as follows:

Market
(MIC Code)
Daily volume (in number of shares) and weighted average price of the purchased
shares, EUR*
Aggregated weekly volume (in number of shares) and weighted weekly average price of the purchased shares, EUR*
    07/09/2026 08/09/2026 09/09/2026 10/09/2026 11/09/2026 Week 37/2026, total
AQEU Volume 25,371 80,848 81,065 52,551 561 240,396
Average price 9.63 9.53 9.38 9.42 9.45 9.47
CEUX Volume 283,865 283,196 274,328 262,471 119,209 1,223,069
Average price 9.66 9.55 9.45 9.45 9.46 9.52
TQEX Volume 41,668 39,642 38,696 36,347 29,489 185,842
Average price 9.67 9.55 9.47 9.44 9.46 9.53
XHEL Volume 510,062 650,176 646,464 643,590 166,571 2,616,863
Average price 9.65 9.54 9.42 9.45 9.46 9.50
Total, all markets Volume 860,966 1,053,862 1,040,553 994,959 315,830 4,266,170
Average price 9.65 9.54 9.43 9.45 9.46 9.51

* rounded to two decimals

On 6 May 2026, Sampo announced a share buyback programme of up to a maximum of EUR 350 million in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052. The programme, which started on 7 May 2026, is based on the authorisation granted by Sampo’s Annual General Meeting on 22 April 2026.

After the disclosed transactions, the company owns in total 30,519,468 Sampo A shares representing 1.15 per cent of the total number of shares in Sampo plc.

Details of each transaction are included as an appendix of this announcement.

On behalf of Sampo plc,
Morgan Stanley Co. International plc

For further information, please contact:

Mirko Hurmerinta
Interim Head of Investor Relations
tel. +358 10 516 0032

Distribution:
Nasdaq Helsinki
Nasdaq Stockholm
Nasdaq Copenhagen
London Stock Exchange
FIN-FSA
The principal media
www.sampo.com

Attachment

Allschwil, Switzerland, September 14, 2026

Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that its partner Asahi Kasei Therapeutics Corp. started a phase 2 clinical study in Japan with the antifungal Cresemba® (isavuconazole) for pediatric patients at risk of deep mycoses.

Dr. Marc Engelhardt, Chief Medical Officer of Basilea, said: “We are very pleased with the start of the pediatric study for Cresemba by our partner Asahi Kasei Therapeutics Corp. Invasive fungal infections pose a critical threat for children suffering from hematologic malignancies or immunodeficiency disorders. Despite this high-risk setting, treatment options remain limited. Making Cresemba available to pediatric patients in Japan would represent a major advance in addressing this important medical need.”

The multicenter, open-label, non-controlled study is assessing the safety and pharmacokinetics of Cresemba in children at risk from deep mycoses.

Cresemba is already approved for the treatment of children in the US, Canada, Europe and China. In Japan, Cresemba is approved for the treatment of adults with severe fungal infections, but currently not for use in pediatric patients.

About Cresemba® (isavuconazole)

Cresemba, with the active ingredient isavuconazole, is an intravenous (i.v.) and oral azole antifungal. Cresemba is marketed in more than 70 countries. In Japan, orally and intravenously administered isavuconazole is approved for use in adults for the treatment of aspergillosis (invasive aspergillosis, chronic progressive pulmonary aspergillosis, simple pulmonary aspergilloma), mucormycosis, and cryptococcosis (pulmonary cryptococcosis and disseminated cryptococcosis). Isavuconazole is also approved in the European Union1, the United Kingdom2, the United States (US)3 and many additional countries, including in the Asia Pacific region.4

According to the latest available market data, total global in-market sales of Cresemba in the twelve-month period between April 2025 and March 2026 amounted to USD 782 million, a 27 percent growth year-on-year, making it the largest branded antifungal for invasive fungal infections worldwide.5

Deep mycoses

Deep mycoses like invasive aspergillosis (IA), invasive mucormycosis (IM) and invasive cryptococcosis are life-threatening fungal infections that spread beyond superficial sites into deep tissues, including lung, eyes, brain, bones, the bloodstream, and other sites or organs. They predominantly affect immunocompromised patients, including patients with hematologic malignancies (blood cancer), transplant patients, or patients with immunodeficiency disorders. These infections are associated with high morbidity and mortality, also in pediatric patients.6, 7, 8

About Basilea

Basilea is a commercial-stage biopharmaceutical company founded in 2000 and headquartered in Switzerland. We are committed to discovering, developing and commercializing innovative drugs to meet the needs of patients with severe bacterial and fungal infections. We have successfully launched two hospital brands, Cresemba for the treatment of invasive fungal infections and Zevtera for the treatment of bacterial infections. In addition, we have preclinical and clinical anti-infective assets in our portfolio. Basilea is listed on the SIX Swiss Exchange (SIX: BSLN). Please visit basilea.com.

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements, such as “believe”, “assume”, “expect”, “forecast”, “project”, “may”, “could”, “might”, “will” or similar expressions concerning Basilea Pharmaceutica Ltd, Allschwil and its business, including with respect to the progress, timing and completion of research, development and clinical studies for product candidates. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Basilea Pharmaceutica Ltd, Allschwil to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Basilea Pharmaceutica Ltd, Allschwil is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

For further information, please contact:

Peer Nils Schröder, PhD

Head of Corporate Communications & Investor Relations
Basilea Pharmaceutica International Ltd, Allschwil
Hegenheimermattweg 167b
4123 Allschwil
Switzerland

Phone +41 61 606 1102
E-mail media_relations@basilea.com
investor_relations@basilea.com

This press release can be downloaded from www.basilea.com.

References

  1. European Public Assessment Report (EPAR) Cresemba: https://www.ema.europa.eu/en/medicines/human/EPAR/cresemba [Accessed: September 13, 2026]
  2. Summary of Product Characteristics (SmPC) Cresemba: https://www.medicines.org.uk/emc/search?q=cresemba [Accessed: September 13, 2026]
  3. Full US prescribing information: https://www.astellas.us/docs/cresemba.pdf [Accessed: September 13, 2026]
  4. The registration status and approved indications may vary from country to country.
  5. IQVIA Analytics Link, March 2026. In-market sales reported as moving annual total (MAT) in US dollar.
  6. J. Cadena, G. R. Thompson 3rd, T. F. Patterson. Aspergillosis: Epidemiology, Diagnosis, and Treatment. Infectious Disease Clinics of North America 2021 (35), 415-434
  7. M. Slavin, S. van Hal, T. C. Sorrell et al. Invasive infections due to filamentous fungi other than Aspergillus: epidemiology and determinants of mortality. Clinical Microbiology and Infection 2015 (21), 490.e1-490.e10
  8. Z. D. Pana E. Roilides, A. Warris et al. Epidemiology of Invasive Fungal Disease in Children. Journal of the Pediatric Infectious Diseases Society 2017 (6), suppl. 1, S3-S11

Attachment

Dear shareholder,

Dear Madam, Dear Sir,

The board of directors invites the shareholders to attend the extraordinary general meeting to be held on Thursday 15 October 2026 at 11.00h at the company’s seat, Begijnenvest 113, 2000 Antwerp. The shareholders are welcome as of 10.00h to facilitate compliance with the admission formalities to the meeting.

Please find attached the convening notice.

All related documents are available online: General Meetings | Ackermans & van Haaren

Best regards

Ackermans & van Haaren

Attachment

Aktsiaselts Infortar acquired its own shares on the Nasdaq Tallinn Stock Exchange during the period of 7 September – 11 September 2026 as follows:

Date Aggregated volume (pcs) Weighted average price per day (EUR)
07.09.2026 216 57,6778
08.09.2026 222 58,1369
09.09.2026 225 60,0000
10.09.2026 227 60,0000
11.09.2026 230 60,0000

Aktsiaselts Infortar is acquiring its own shares based on the stock exchange announcement published on 20 April 2026. The share buyback programme is managed by SEB Pank AS, which will buy back shares on behalf of Aktsiaselts Infortar.

Summary data (daily volume and weighted average prices) will be disclosed no later than on the seventh trading day following the transaction and be made available to the Estonian Financial Supervision and Resolution Authority, via the Nasdaq Tallinn system, and on Aktsiaselts Infortar´s investor website.

Further detailed information on the transactions is attached.

Infortar operates in seven countries, the company’s main fields of activity are maritime transport, energy and real estate. Infortar owns a 68.83% shareholding in Tallink Grupp, a 100% share in Elenger Grupp and a versatile and modern real estate portfolio of approx. 141,000 m2. In addition to the three main areas of activity, Infortar also operates in construction and mineral resources, agriculture, and other areas. A total of 107 companies belong to the Infortar group, including 3 associates and 2 subsidiaries of associates. Infortar employs 6890 people.

Additional information:

Kadri Laanvee
Investor Relations Manager
Phone: +372 5156662
e-mail: kadri.laanvee@infortar.ee
www.infortar.ee/en/investor

Attachment

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.